Cereblon isoforms and their use as biomarkers for therapeutic treatment
AssigneeCelgene Corporation
InventorsAnjan THAKURTA, Anita GANDHI, Michelle F. WALDMAN, Rajesh CHOPRA, Michael AMATANGELO, Chad BJORKLUND
Life of this patent
Estimating the term…
Abstract
Provided herein are cereblon isoforms and methods of their use as biomarkers for treating a disease, disorder, or condition with a treatment compound, e.g., thalidomide, lenalidomide, pomalidomide, 3-(5-amino-2-methyl-4-oxoquinazolin-3 (4H)-yl)-piperidine-2,6-dione, or (S)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione.
Claims20
-31. (canceled)
A method of identifying a subject having multiple myeloma who is likely to be responsive to a treatment with a treatment compound, comprising:
- a) determining the level of a biomarker in a biological sample from the subject, wherein the biomarker is an isoform of cereblon (CRBN), the isoform of CRBN having a deletion in exon 10 of CRBN;
- and
- b) comparing the level of the biomarker in the biological sample from the subject to a reference level of the biomarker;
- wherein the subject is likely to be responsive to the treatment if the level of the biomarker in the biological sample from the subject is altered as compared to the reference level of the biomarker.
-49. (canceled)
-102. (canceled)
A method of selectively treating a subject having multiple myeloma, comprising:
- a) determining the level of a biomarker in a biological sample from the subject, wherein the biomarker is an isoform of cereblon (CRBN), the isoform of CRBN having a deletion in exon 10 of CRBN;
- b) comparing the level of the biomarker in the biological sample from the subject to a reference level of the biomarker;
- c) administering a treatment compound to the subject, wherein the level of the biomarker in the biological sample from the subject is altered as compared to the reference level of the biomarker.
Dependencies are inferred from the claim text.